<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618916</url>
  </required_header>
  <id_info>
    <org_study_id>14354</org_study_id>
    <secondary_id>I5S-EW-EFJB</secondary_id>
    <nct_id>NCT01618916</nct_id>
  </id_info>
  <brief_title>A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol</brief_title>
  <official_title>A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Japanese and Non-Japanese Subjects With Elevated LDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study in otherwise healthy participants with high LDL cholesterol.
      Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body
      handles the drug, and the drug's effect on the body will be evaluated. Participants will
      participate in the study for approximately 3 months not including screening. Screening is
      required within 42 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with one or more drug related adverse events (AEs) or any serious AEs</measure>
    <time_frame>Baseline to study completion (Day 127)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of LY3015014</measure>
    <time_frame>Baseline up to Day 127</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration curve (AUC) of LY3015014</measure>
    <time_frame>Baseline up to Day 127</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of maximum concentration (Tmax) of LY3015014</measure>
    <time_frame>Baseline up to Day 127</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 127 in low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Day 127</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1.0 mg/kg LY3015014 Every 2 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 milligrams per kilogram (mg/kg) LY3015014 given subcutaneously (SQ) once every 2 weeks for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/kg LY3015014 Every 4 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg LY3015014 given SQ once every 4 weeks for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg/kg LY3015014 Every 2 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg LY3015014 given SQ once every 2 weeks for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg/kg LY3015014 Every 4 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg LY3015014 given SQ once every 4 weeks for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Every 2 Weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline injection (to match LY3015014) given SQ once every 2 weeks for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Every 4 Weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline injection (to match LY3015014) given SQ once every 4 weeks for 29 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3015014</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>1.0 mg/kg LY3015014 Every 2 Weeks</arm_group_label>
    <arm_group_label>1.0 mg/kg LY3015014 Every 4 Weeks</arm_group_label>
    <arm_group_label>3.0 mg/kg LY3015014 Every 2 Weeks</arm_group_label>
    <arm_group_label>3.0 mg/kg LY3015014 Every 4 Weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Placebo Every 2 Weeks</arm_group_label>
    <arm_group_label>Placebo Every 4 Weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be healthy males or females without childbearing potential as
             determined by medical history and physical examination, including first-generation
             Japanese participants

          -  Have body mass indexes of 18 to 35 kg/m^2, inclusive, at screening

          -  Have screening low-density lipoprotein cholesterol (LDL-Cs) of between 100 and 180
             milligrams per deciliter (mg/dL), inclusive

        Exclusion Criteria:

          -  Have known allergies to compounds related to LY3015014 or any components of the
             formulation or known clinically significant hypersensitivity to biologic agents

          -  Have a history of atopy, significant allergies to humanized monoclonal antibodies,
             clinically significant multiple or severe drug allergies, intolerance to topical
             corticosteroids, or severe posttreatment hypersensitivity reactions (including but not
             limited to erythema multiforme major, linear immunoglobulin [Ig]A dermatosis, toxic
             epidermal necrolysis, or exfoliative dermatitis)

          -  Have significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs, of
             constituting a risk when taking the study medication, or of interfering with the
             interpretation of data

          -  Have received any vaccine(s) within 1 month of LY3015014 dosing or intend to do so
             during the study

          -  Have received treatment with biologic agents (such as monoclonal antibodies) within 3
             months or 5 half-lives (whichever is longer) prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <last_update_submitted>February 26, 2013</last_update_submitted>
  <last_update_submitted_qc>February 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

